These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23176136)

  • 1. A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.
    Yu B; Wang Z; Dong J; Wang C; Gu L; Sun C; Kong W; Yu X
    Virol J; 2012 Nov; 9():287. PubMed ID: 23176136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
    Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
    Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
    Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
    Mast TC; Kierstead L; Gupta SB; Nikas AA; Kallas EG; Novitsky V; Mbewe B; Pitisuttithum P; Schechter M; Vardas E; Wolfe ND; Aste-Amezaga M; Casimiro DR; Coplan P; Straus WL; Shiver JW
    Vaccine; 2010 Jan; 28(4):950-7. PubMed ID: 19925902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
    Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
    J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.
    Appaiahgari MB; Pandey RM; Vrati S
    Clin Vaccine Immunol; 2007 Aug; 14(8):1053-5. PubMed ID: 17596429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
    Zheng X; Rong X; Feng Y; Sun X; Li L; Wang Q; Wang M; Liu W; Li C; Yang Y; Zhou R; Lu J; Feng L; Chen L
    Emerg Microbes Infect; 2017 Jun; 6(6):e43. PubMed ID: 28588291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
    Thorner AR; Vogels R; Kaspers J; Weverling GJ; Holterman L; Lemckert AA; Dilraj A; McNally LM; Jeena PM; Jepsen S; Abbink P; Nanda A; Swanson PE; Bates AT; O'Brien KL; Havenga MJ; Goudsmit J; Barouch DH
    J Clin Microbiol; 2006 Oct; 44(10):3781-3. PubMed ID: 17021110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.
    Yu B; Zhou Y; Wu H; Wang Z; Zhan Y; Feng X; Geng R; Wu Y; Kong W; Yu X
    J Med Virol; 2012 Sep; 84(9):1408-14. PubMed ID: 22825819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
    Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH
    J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology.
    Yu B; Dong J; Wang C; Wang Z; Gao L; Zhang H; Wu J; Kong W; Yu X
    J Gen Virol; 2014 Jul; 95(Pt 7):1564-1573. PubMed ID: 24764358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
    Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
    J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China.
    Sun C; Zhang Y; Feng L; Pan W; Zhang M; Hong Z; Ma X; Chen X; Chen L
    Vaccine; 2011 May; 29(22):3837-41. PubMed ID: 21447314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.
    Piedra PA; Poveda GA; Ramsey B; McCoy K; Hiatt PW
    Pediatrics; 1998 Jun; 101(6):1013-9. PubMed ID: 9606228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
    Front Immunol; 2018; 9():335. PubMed ID: 29563911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa.
    Wang B; Li J; Wu S; Chen Y; Zhang Z; Zhai Y; Guo Q; Zhang J; Song X; Zhao Z; Hou L; Chen W
    Emerg Microbes Infect; 2018 Dec; 7(1):200. PubMed ID: 30514848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
    Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
    Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
    Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
    Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
    Pilankatta R; Chawla T; Khanna N; Swaminathan S
    J Med Virol; 2010 Mar; 82(3):407-14. PubMed ID: 20087930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Infection rate with adenivirus 1 to 39 in infants and adults].
    Fatz W; Wigand R
    Immun Infekt; 1985 May; 13(3):108-12. PubMed ID: 2408993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.